One investigation indicated that the pairing of BRAF inhibitors with EGFR monoclonal antibodies encouraged a temporary MSI-H phenotype in MSS-type bowel cancer, hinting at potentially improved survival outcomes for patients harboring BRAF mutations. Here, BRAF is linked to intestinal cancer.